| 2.21 0.01 (0.45%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.96 |
1-year : | 3.62 |
| Resists | First : | 2.53 |
Second : | 3.09 |
| Pivot price | 2.04  |
|||
| Supports | First : | 1.62 |
Second : | 1.34 |
| MAs | MA(5) : | 2.09 |
MA(20) : | 2.09 |
| MA(100) : | 2.02 |
MA(250) : | 4.96 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31 |
D(3) : | 24.4 |
| RSI | RSI(14): 56.5 | |||
| 52-week | High : | 11 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TFFP ] has closed below upper band by 21.2%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.28 - 2.29 | 2.29 - 2.3 |
| Low: | 2.16 - 2.18 | 2.18 - 2.19 |
| Close: | 2.19 - 2.21 | 2.21 - 2.23 |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Thu, 12 Sep 2024
TFF Pharmaceuticals partners with Emory University on antiviral tech - Investing.com
Tue, 10 Sep 2024
TFF Pharmaceuticals reports progress in universal flu vaccine - Investing.com
Tue, 03 Sep 2024
TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Sat, 17 Aug 2024
TFF Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 22.5 (%) |
| Shares Short | 144 (K) |
| Shares Short P.Month | 129 (K) |
| EPS | -6.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | 0 % |
| Operating Margin | -609.5 % |
| Return on Assets (ttm) | -106 % |
| Return on Equity (ttm) | -213.6 % |
| Qtrly Rev. Growth | 95 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.34 |
| EBITDA (p.s.) | -5.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.33 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 6.39 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|